277 related articles for article (PubMed ID: 1379965)
1. Orgaran (Org 10172): its pharmacological profile in experimental models.
Meuleman DG
Haemostasis; 1992; 22(2):58-65. PubMed ID: 1379965
[TBL] [Abstract][Full Text] [Related]
2. Synopsis of the anticoagulant and antithrombotic profile of the low molecular weight heparinoid Org 10172 in experimental models.
Meuleman DG
Semin Thromb Hemost; 1989 Oct; 15(4):370-2. PubMed ID: 2479103
[TBL] [Abstract][Full Text] [Related]
3. Anticoagulant mechanisms of Orgaran (Org 10172) and its fraction with high affinity to antithrombin III (Org 10849).
Ofosu FA
Haemostasis; 1992; 22(2):66-72. PubMed ID: 1379966
[TBL] [Abstract][Full Text] [Related]
4. Pentasaccharide and Orgaran arrest, whereas heparin delays thrombus formation in a rat arteriovenous shunt.
Vogel GM; van Amsterdam RG; Kop WJ; Meuleman DG
Thromb Haemost; 1993 Jan; 69(1):29-34. PubMed ID: 8446935
[TBL] [Abstract][Full Text] [Related]
5. A novel anti-thrombotic heparinoid (Org 10172) devoid of bleeding inducing capacity: a survey of its pharmacological properties in experimental animal models.
Meuleman DG; Hobbelen PM; van Dedem G; Moelker HC
Thromb Res; 1982 Aug; 27(3):353-63. PubMed ID: 6182627
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic considerations on Orgaran (Org 10172) therapy.
Danhof M; de Boer A; Magnani HN; Stiekema JC
Haemostasis; 1992; 22(2):73-84. PubMed ID: 1379967
[TBL] [Abstract][Full Text] [Related]
7. Low-affinity material does not contribute to the antithrombotic activity of Orgaran (Org 10172) in human plasma.
Zammit A; Dawes J
Thromb Haemost; 1994 Jun; 71(6):759-67. PubMed ID: 7526481
[TBL] [Abstract][Full Text] [Related]
8. Orgaran in the prevention of deep vein thrombosis in stroke patients.
Turpie AG
Haemostasis; 1992; 22(2):92-8. PubMed ID: 1379969
[TBL] [Abstract][Full Text] [Related]
9. Time courses of the antithrombotic effects, bleeding enhancing effects and interactions with factors Xa and thrombin after administration of low molecular weight heparinoid Org 10172 or heparin to rats.
Hobbelen PM; Vogel GM; Meuleman DG
Thromb Res; 1987 Dec; 48(5):549-58. PubMed ID: 3481660
[TBL] [Abstract][Full Text] [Related]
10. In vivo activity of a new heparinoid.
Ockelford PA; Carter CJ; Hirsh J
Pathology; 1985 Jan; 17(1):78-81. PubMed ID: 4000717
[TBL] [Abstract][Full Text] [Related]
11. A cross-over comparison of the anti-clotting effects of three low molecular weight heparins and glycosaminoglycuronan.
Stiekema JC; Van Griensven JM; Van Dinther TG; Cohen AF
Br J Clin Pharmacol; 1993 Jul; 36(1):51-6. PubMed ID: 8396956
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological and clinical studies with Lomoparan, a low molecular weight glycosaminoglycan.
Nurmohamed MT; Fareed J; Hoppensteadt D; Walenga JM; ten Cate JW
Semin Thromb Hemost; 1991; 17 Suppl 2():205-13. PubMed ID: 1948091
[No Abstract] [Full Text] [Related]
13. Heparan sulfate and dermatan sulfate inhibit the generation of thrombin activity in plasma by complementary pathways.
Ofosu FA; Modi GJ; Smith LM; Cerskus AL; Hirsh J; Blajchman MA
Blood; 1984 Sep; 64(3):742-7. PubMed ID: 6235872
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms for the anticoagulant effect of heparin and related polysaccharides.
Ofosu FA
Nouv Rev Fr Hematol (1978); 1988; 30(3):155-60. PubMed ID: 2971155
[TBL] [Abstract][Full Text] [Related]
15. Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with orgaran (Org 10172).
Magnani HN
Thromb Haemost; 1993 Oct; 70(4):554-61. PubMed ID: 7509508
[TBL] [Abstract][Full Text] [Related]
16. A randomized blind study comparing standard heparin and a new low molecular weight heparinoid in cardiopulmonary bypass surgery in dogs.
Henny CP; Ten Cate H; Ten Cate JW; Moulijn AC; Sie TH; Warren P; Büller HR
J Lab Clin Med; 1985 Aug; 106(2):187-96. PubMed ID: 4020247
[TBL] [Abstract][Full Text] [Related]
17. Orgaran (Org 10172) or heparin for preventing venous thrombosis after elective surgery for malignant disease? A double-blind, randomised, multicentre comparison. ANZ-Organon Investigators' Group.
Gallus A; Cade J; Ockelford P; Hepburn S; Maas M; Magnani H; Bucknall T; Stevens J; Porteous F
Thromb Haemost; 1993 Oct; 70(4):562-7. PubMed ID: 7509509
[TBL] [Abstract][Full Text] [Related]
18. Anticoagulant effects of a low molecular weight heparinoid (Org 10172) in human volunteers and haemodialysis patients.
ten Cate H; Henny CP; ten Cate JW; Büller HR; Mooy MC; Surachno S; Wilmink JM
Thromb Res; 1985 Jul; 39(2):211-22. PubMed ID: 3161213
[TBL] [Abstract][Full Text] [Related]
19. Influence of heparin and a low molecular weight heparinoid on specific endogenous and exogenous fibrinolytic factors during rest and exercise.
de Boer A; Kluft C; Dooijewaard G; Kasper FJ; Kroon JM; Breimer DD; Stiekema JC; Cohen AF
Thromb Haemost; 1992 Nov; 68(5):550-5. PubMed ID: 1280862
[TBL] [Abstract][Full Text] [Related]
20. The use of low dose Orgaran in heparin-induced thrombocytopenia associated with in vitro platelet aggregation at higher Orgaran concentrations.
Hill GR; Hickton C; Henderson S; Patton WN
Clin Lab Haematol; 1997 Jun; 19(2):155-7. PubMed ID: 9218159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
